Universal Biosensors (UBI) is
focused on the research, development and manufacture of diagnostic test systems
for point-of-care (POC) professional and home use. The point-of-care diagnostic
market is worth ~US$15 billion a year and growing.
UBI’s core technology is a
disposable, multi-layer test strip, which incorporates a proprietary electrochemical
sensing system that rapidly and accurately measures biomarkers in the
blood. This technology offers speed,
ease of use, reliability and accuracy at a low cost.
UBI has partnered with global
healthcare company Siemens Healthcare to develop the Xprecia StrideTM blood
coagulation analyser, launched in December 2014, to help patients taking the anti-coagulant
drug Warfarin manage their medication.
UBI has also developed a blood
glucose monitoring product that is being commercialised globally by LifeScan,
Inc. (a Johnson & Johnson company) under the OneTouch® Verio®
UBI's innovative electrochemical
sensor platform is being applied to a range of other medical diagnostic